One of the more spurious and naive arguments proffered by the industry's antagonists and even some people in government is that the pricing of new treatments should reflect whether public funding contributed in any way to its development. …
Latest Video
New Stories
-
The 'Dispatched' Week in Review' Podcast - 31 July
July 31, 2026 - - Podcast -
New partnership aims to create national blueprint for earlier Alzheimer’s diagnosis and care
July 31, 2026 - - Latest News -
Industry associations still resisting non-disclosure agreements for negotiation
July 31, 2026 - - Latest News -
AUScelerate programs channel major investment into heart and diabetes innovations
July 30, 2026 - - Latest News -
New AusBiotech membership aims to help Australia’s early-stage life sciences founders thrive
July 30, 2026 - - Latest News -
CSL begins clinical trials to test higher-yield plasma manufacturing
July 30, 2026 - - Latest News -
AI will likely grow the HTA 'industrial complex', but it can also democratise the institution
July 30, 2026 - - Latest News